JH
Jeffrey Hung Morgan Stanley Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$14.3B
| $144.10 | $163 |
13%
upside
| Overweight | 2 days ago |
|
2
Jazz Pharmaceuticals
JAZZ
$7.86B
| $129.50 | $163 |
26%
upside
| Overweight | 10 days ago |
|
3
PTC Therapeutics
PTCT
$4.55B
| $57.26 | $71 |
24%
upside
| Overweight | 18 days ago |
|
4
Cullinan Oncology
CGEM
$413M
| $6.99 | $28 |
301%
upside
| Overweight | 20 days ago |
|
|
CTNM
5
Contineum Therapeutics
CTNM
$322M
| $11.50 | $21 |
83%
upside
| Overweight | 20 days ago |
|
6
Erasca
ERAS
$457M
| $1.61 | $2 |
24%
upside
| Equal-Weight | 20 days ago |
|
|
BCYC
7
Bicycle Therapeutics
BCYC
$496M
| $7.16 | $13 |
82%
upside
| Equal-Weight | 26 days ago |
|
8
Rhythm Pharmaceuticals
RYTM
$6.78B
| $102.12 | $109 |
7%
upside
| Overweight | 1 month ago |
|
9
Amicus Therapeutics
FOLD
$2.46B
| $7.99 | $108 |
1,252%
upside
| Overweight | 1 month ago |
|
10
Ultragenyx Pharmaceutical
RARE
$3.07B
| $31.82 | $55 |
73%
upside
| Overweight | 1 month ago |
|
11
CG Oncology
CGON
$2.52B
| $33.07 | $56 |
69%
upside
| Overweight | 2 months ago |
|
12
Acadia Pharmaceuticals
ACAD
$4.26B
| $25.26 | $24 |
5%
downside
| Equal-Weight | 3 months ago |
|
13
enGene Holdings
ENGN
$265M
| $5.18 | $34 |
556%
upside
| Overweight | 6 months ago |
|
14
Disc Medicine
IRON
$2.11B
| $60.76 | $85 |
40%
upside
| Overweight | 6 months ago |
|
|
CNTA
15
Centessa Pharmaceuticals
CNTA
$2.11B
| $15.73 | $27 |
72%
upside
| Overweight | 6 months ago |
|
16
Cytokinetics
CYTK
$6.34B
| $53.01 | $67 |
26%
upside
| Overweight | 6 months ago |
|
17
Crinetics Pharmaceuticals
CRNX
$3.35B
| $35.61 | $70 |
97%
upside
| Overweight | 1 year ago |
|
18
ADC Therapeutics
ADCT
$398M
| $3.54 | $5 |
41%
upside
| Equal-Weight | 2 years ago |
|
19
Esperion Therapeutics
ESPR
$540M
| $2.68 | $3 |
12%
upside
| Equal-Weight | 2 years ago |
|
20
Exelixis
EXEL
$10.2B
| $37.88 | $22 |
42%
downside
| Equal-Weight | 2 years ago |
|
21
Biohaven
BHVN
$1.68B
| $15.87 | $148.50 |
836%
upside
| Equal-Weight | 3 years ago |
|